Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 16/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL259117 | 0.75 | PDE10A (0.51) | PDE10AKMT2ATP53KDM4EALDH1A1 | |
| SCHEMBL5953401 | 0.70 | HRH3 (0.51) | PDE10AHRH3KMT2ATP53KDM4E | |
| SCHEMBL3179987 | 0.70 | ALDH1A1 (0.59) | PDE10AKMT2ATP53KDM4EALDH1A1 | |
| SCHEMBL260196 | 0.70 | NPC1 (0.61) | PDE10AHRH3KMT2ATP53KDM4E | |
| SCHEMBL10168099 | 0.69 | PDE10A (0.42) | PDE10AKMT2ATP53KDM4EALDH1A1 | |
| SCHEMBL3185397 | 0.69 | PDE10A (0.57) | PDE10A | |
| SCHEMBL259300 | 0.69 | PDE10A (0.54) | PDE10AHRH3KMT2ATP53KDM4E | |
| SCHEMBL258901 | 0.69 | PDE10A (1.00) | PDE10A | |
| SCHEMBL651412 | 0.69 | MAP4K4 (0.47) | PDE10AKMT2ATP53ALDH1A1MAPT | |
| SCHEMBL259372 | 0.68 | PDE10A (0.58) | PDE10ATP53KDM4EPKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9018217-B2 | Phenylimidazole derivatives as PDE10A enzyme inhibitors | H. LUNDBECK A/S (DK) | 2015-04-28 | — | — | US | claimed |
| US-20150025081-A1 | NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2015-01-22 | — | — | US | claimed |
| EP-2318394-B1 | NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | LUNDBECK & CO AS H (DK) | 2014-01-22 | — | — | EP | claimed |
| US-20120135987-A1 | NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2012-05-31 | — | — | US | claimed |
| US-20100016303-A1 | NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2010-01-21 | — | — | US | claimed |
| US-9592230-B2 | Substituted imidazoles as PDE10A inhibitors | H. LUNDBECK A/S (DK) | 2017-03-14 | — | — | US | disclosed |
| US-20150190395-A1 | Novel Phenylimidazole Derivatives as PDE10A Enzyme Inhibitors | H. LUNDBECK A/S (DK) | 2015-07-09 | — | — | US | disclosed |
| US-20150025081-A1 | NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2015-01-22 | — | — | US | disclosed |
| US-8865711-B2 | Phenylimidazole derivatives as PDE10A enzyme inhibitors | H. LUNDBECK A/S (DK) | 2014-10-21 | — | — | US | disclosed |
| EP-2318394-B1 | NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | LUNDBECK & CO AS H (DK) | 2014-01-22 | — | — | EP | disclosed |
| US-20120135987-A1 | NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2012-05-31 | — | — | US | disclosed |
| US-8133897-B2 | Phenylimidazole derivatives as PDE10A enzyme inhibitors | H. LUNDBECK A/S (DK) | 2012-03-13 | — | — | US | disclosed |
| US-20100016303-A1 | NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016303-A1 | NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | PDE10A, PDE5A, PDE3B | PDE10A 1/4885HRH3 3611/4885KMT2A 1113/4885 |
| US-20150190395-A1 | Novel Phenylimidazole Derivatives as PDE10A Enzyme Inhibitors | PDE10A, PDE5A, PDE3B | PDE10A 1/4885HRH3 3611/4885KMT2A 1113/4885 |
| US-20120135987-A1 | NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | PDE10A, PDE5A, PDE3B | PDE10A 1/4885HRH3 3611/4885KMT2A 1113/4885 |
| US-20150025081-A1 | NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | PDE10A, PDE5A, PDE3B | PDE10A 1/4885HRH3 3611/4885KMT2A 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.